Answers are grounded in this paper and cite their sources.
The clinical eVects of botulinum toxin have been recognised since the end of the 19th century. It is the most potent neurotoxin known and it is produced by the gram negative anaerobic bacterium Clostridium botulinum. The paralytic eVect of the toxin is due to blockade of neuromuscular transmission. 1 Injection into a muscle causes chemodenervation and local paralysis and this eVect has led to the development of the toxin as a therapeutic tool. It is now used clinically for a wide range of conditions, 2 particularly focal dystonias, and increasingly for spasticity. This paper reviews the mode of action of botulinum and focuses on its use in the management of spasticity.
No takes yet. Share an insight, caveat, or question.
Elizabeth C. Davis (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: